Categories: Pennsylvania Business NewsPennsylvania News

Ecolab Opens New Bioprocessing Laboratory in Pennsylvania

Ecolab's new laboratory designed for bioprocessing applications in the biopharmaceutical industry.

News Summary

Ecolab has launched a cutting-edge bioprocessing laboratory in King of Prussia, PA, aimed at supporting the biopharmaceutical industry. This facility enhances capabilities in developing and purifying biotherapeutic molecules. Part of a larger $40 million investment linked to Ecolab’s acquisition of Purolite, the lab features advanced tools to accelerate drug development, starting with a treatment for high cholesterol. Positioned strategically near major pharmaceutical operations, this lab signifies Ecolab’s commitment to innovation in life sciences.

Pennsylvania — Ecolab, a global leader in water, hygiene, and energy technologies, has officially opened a new laboratory focused on bioprocessing applications in King of Prussia. This state-of-the-art facility is designed to support the biopharmaceutical industry in developing and purifying biotherapeutic molecules effectively.

The lab is part of Ecolab’s existing 74,000 square feet facility, which began operations in 2022 following Ecolab’s acquisition of Purolite, a manufacturer of resin technologies, in a deal worth $3.7 billion. The expansion of lab capabilities reflects Ecolab’s commitment to enhancing its life sciences division, which is headquartered in King of Prussia and employs around 75 individuals.

Strategically located near several major pharmaceutical operations on the East Coast, Ecolab’s new lab aims to improve collaboration with pharmaceutical organizations during all stages of drug development, from initial research to commercialization. This collaboration is essential, especially as the industry faces increasing pressure to expedite the development and manufacturing processes.

Notably, the facility has already initiated a pilot program, which began in late 2024, prior to the official opening. This program is designed to accelerate the lifecycle studies for biopharma customers, enhancing both speed and efficiency in manufacturing. The lab is equipped with advanced high-throughput process development tools and chromatography columns applicable for manufacturing scale, which is crucial for large-scale biotherapeutics production.

The initial product slated for production at the new lab involves a treatment for high cholesterol, using raw materials sourced from Purolite’s processing plant in Romania. This project highlights Ecolab’s capability to streamline operations and address previous capacity issues encountered during its investment in resin technology.

Local reports indicate that the overall investment in constructing the larger facility reached approximately $40 million, marking it as a significant commitment to expanding Ecolab’s presence in the biopharmaceutical sector. The establishment of this lab is seen as a key milestone for the company, particularly in fostering global technical partnerships that enhance product offerings and capabilities in the life sciences field.

As the biopharma industry continues to evolve, Ecolab’s King of Prussia location is poised to play a vital role in meeting the increasing demands for biotherapeutic solutions. The new bioprocessing laboratory stands as a testament to the organization’s ongoing efforts to innovate and provide advanced resources to its clients in the pharmaceutical sector.